MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
MAIA Biotechnology (NYSE: MAIA) announced its selection to present a poster at the European Lung Cancer Congress 2025 (ELCC 2025) in Paris, France, from March 26-29. The presentation will focus on cytokine Interleukin-6 (IL-6) as a potential predictive biomarker for THIO treatment response in advanced non-small cell lung cancer (NSCLC).
The poster will highlight findings related to THIO's mechanisms of action when sequenced with checkpoint inhibitors, following exceptional efficacy demonstrated in the company's Phase 2 clinical trial. The ELCC, a program of the European Society for Medical Oncology (ESMO), brings together key multidisciplinary societies in thoracic oncology to advance science and improve lung cancer specialist practices.
MAIA Biotechnology (NYSE: MAIA) ha annunciato la sua selezione per presentare un poster al Congresso Europeo sul Cancro del Polmone 2025 (ELCC 2025) che si terrà a Parigi, Francia, dal 26 al 29 marzo. La presentazione si concentrerà sulla citochina Interleuchina-6 (IL-6) come potenziale biomarcatore predittivo per la risposta al trattamento con THIO nel cancro polmonare non a piccole cellule avanzato (NSCLC).
Il poster metterà in evidenza i risultati relativi ai meccanismi d'azione di THIO quando sequenziato con inibitori dei checkpoint, a seguito dell'eccezionale efficacia dimostrata nel trial clinico di Fase 2 dell'azienda. L'ELCC, un programma della Società Europea di Oncologia Medica (ESMO), riunisce importanti società multidisciplinari nell'oncologia toracica per promuovere la scienza e migliorare le pratiche degli specialisti del cancro al polmone.
MAIA Biotechnology (NYSE: MAIA) anunció su selección para presentar un póster en el Congreso Europeo de Cáncer de Pulmón 2025 (ELCC 2025) en París, Francia, del 26 al 29 de marzo. La presentación se centrará en la citoquina Interleucina-6 (IL-6) como un posible biomarcador predictivo para la respuesta al tratamiento con THIO en el cáncer de pulmón no microcítico avanzado (NSCLC).
El póster destacará los hallazgos relacionados con los mecanismos de acción de THIO cuando se secuencia con inhibidores de puntos de control, tras la excepcional eficacia demostrada en el ensayo clínico de Fase 2 de la empresa. ELCC, un programa de la Sociedad Europea de Oncología Médica (ESMO), reúne a sociedades multidisciplinarias clave en oncología torácica para avanzar en la ciencia y mejorar las prácticas de los especialistas en cáncer de pulmón.
MAIA Biotechnology (NYSE: MAIA)는 2025년 3월 26일부터 29일까지 프랑스 파리에서 열리는 유럽 폐암 학회 2025 (ELCC 2025)에서 포스터 발표를 하게 되었다고 발표했습니다. 발표는 고급 비소세포 폐암(NSCLC)에서 THIO 치료 반응의 잠재적 예측 바이오마커로서 사이토카인 인터루킨-6(IL-6)에 초점을 맞출 것입니다.
이 포스터는 체크포인트 억제제와 함께 시퀀스 되었을 때 THIO의 작용 메커니즘과 관련된 발견을 강조할 것입니다. 이는 회사의 2상 임상 시험에서 입증된 예외적인 효능에 따른 것입니다. ELCC는 유럽 종양학회(ESMO)의 프로그램으로, 흉부 종양학의 주요 다학제 사회를 모아 과학을 발전시키고 폐암 전문가의 실습을 개선합니다.
MAIA Biotechnology (NYSE: MAIA) a annoncé sa sélection pour présenter un poster lors du Congrès Européen sur le Cancer du Poumon 2025 (ELCC 2025) à Paris, France, du 26 au 29 mars. La présentation se concentrera sur la cytokine Interleukine-6 (IL-6) en tant que biomarqueur prédictif potentiel pour la réponse au traitement par THIO dans le cancer du poumon non à petites cellules avancé (NSCLC).
Le poster mettra en lumière les résultats liés aux mécanismes d'action de THIO lorsqu'il est séquencé avec des inhibiteurs de points de contrôle, suite à l'efficacité exceptionnelle démontrée dans l'essai clinique de Phase 2 de l'entreprise. L'ELCC, un programme de la Société Européenne d'Oncologie Médicale (ESMO), réunit des sociétés multidisciplinaires clés en oncologie thoracique pour faire avancer la science et améliorer les pratiques des spécialistes du cancer du poumon.
MAIA Biotechnology (NYSE: MAIA) gab bekannt, dass sie ausgewählt wurde, um ein Poster auf dem Europäischen Lungenkrebs-Kongress 2025 (ELCC 2025) in Paris, Frankreich, vom 26. bis 29. März zu präsentieren. Die Präsentation wird sich auf das Zytokin Interleukin-6 (IL-6) als potenziellen prädiktiven Biomarker für die THIO-Behandlungsreaktion bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC) konzentrieren.
Das Poster wird Ergebnisse zu den Wirkmechanismen von THIO hervorheben, wenn es in Kombination mit Checkpoint-Inhibitoren angewendet wird, nach der außergewöhnlichen Wirksamkeit, die in der Phase-2-Studie des Unternehmens gezeigt wurde. Der ELCC, ein Programm der Europäischen Gesellschaft für Medizinische Onkologie (ESMO), vereint wichtige multidisziplinäre Gesellschaften in der Thoraxonkologie, um die Wissenschaft voranzutreiben und die Praktiken von Lungenkrebsspezialisten zu verbessern.
- Phase 2 clinical trial showed exceptional efficacy for THIO treatment
- Identification of potential predictive biomarker (IL-6) for treatment response
- None.
- Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)
“We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology,” said Vlad Vitoc, M.D., CEO of MAIA. “Our poster features our latest findings on cytokine Interleukin-6 (IL-6) as a potential predictive immune response biomarker for THIO sequenced with a checkpoint inhibitor. Predictive biomarkers can further illuminate THIO’s unique mechanisms of action which have shown exceptional efficacy in our Phase 2 clinical trial.”
Presentation details: |
|
|
Title: |
Phase 2 Study of Telomere-Targeting Agent THIO Sequenced by Cemiplimab in Immune Checkpoint Inhibitor-Resistant Advanced NSCLC: Interleukin-6 as a Potential Predictive Biomarker |
|
Abstract number: |
997 |
|
Date: |
March 28, 2025 |
|
Time: |
12:00 p.m. CET |
|
Presenter: |
Tomasz Jankowski, M.D., Ph.D. – Lead investigator for THIO-101 Phase 2 clinical trial |
|
Poster access: |
MAIA’s poster will be available at maiabiotech.com/publications on March 28, 2025 |
The European Lung Cancer Congress is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325817866/en/
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
Source: MAIA Biotechnology, Inc.
FAQ
What will MAIA Biotechnology present at ELCC 2025?
When and where will MAIA's ELCC 2025 presentation take place?
What were the results of MAIA's Phase 2 trial for THIO treatment?
What is the significance of IL-6 biomarker in MAIA's THIO treatment?
